Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rachel Riera is active.

Publication


Featured researches published by Rachel Riera.


Radiotherapy and Oncology | 2014

Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis.

Gustavo Nader Marta; Valter Silva; Heloisa de Andrade Carvalho; Fernando Freire Arruda; Samir Abdallah Hanna; Rafael Gadia; João Luis Fernandes da Silva; Sebastião Francisco Miranda Correa; Carlos Eduardo Cintra Vita Abreu; Rachel Riera

BACKGROUND AND PURPOSE Intensity-modulated radiation therapy (IMRT) provides the possibility of dose-escalation with better normal tissue sparing. This study was performed to assess whether IMRT can improve clinical outcomes when compared with two-dimensional (2D-RT) or three-dimensional conformal radiation therapy (3D-CRT) in patients with head and neck cancer. METHODS AND MATERIALS Only prospective phase III randomized trials comparing IMRT with 2D-RT or 3D-CRT were eligible. Combined surgery and/or chemotherapy were allowed. Two authors independently selected and assessed the studies regarding eligibility criteria and risk of bias. RESULTS Five studies were selected. A total of 871 patients were randomly assigned for 2D-RT or 3D-CRT (437), versus IMRT (434). Most patients presented with nasopharyngeal cancers (82%), and stages III/IV (62.1%). Three studies were classified as having unclear risk and two as high risk of bias. A significant overall benefit in favor of IMRT was found (hazard ratio - HR=0.76; 95% CI: 0.66, 0.87; p<0.0001) regarding xerostomia scores grade 2-4, with similar loco-regional control and overall survival. CONCLUSIONS IMRT reduces the incidence of grade 2-4 xerostomia in patients with head and neck cancers without compromising loco-regional control and overall survival.


Journal of Clinical Psychopharmacology | 2012

Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis.

Fábio Lopes Rocha; Cíntia Fuzikawa; Rachel Riera; Cláudia Hara

Abstract The objective was to perform a systematic review and meta-analysis of studies that assessed the effect of the combination of antidepressants from the beginning of the treatment of major depressive disorder. Studies were retrieved from PubMed (1966 to August 2010), Cochrane Library (August 2010), Embase (1980 to August 2010), PsycINFO (1980 to August 2010), Lilacs (1982 to August 2010), clinical trials registry, thesis database (www.capes.gov.br), and secondary references. All randomized controlled trials that compared a combination of antidepressants with a single antidepressant from the beginning of the treatment of major depressive disorder in adults were included. Data analysis was performed using the Review Manager 5.0. Of 3492 studies retrieved, five satisfied the inclusion criteria. In one study, only data about dropouts were included. Antidepressant combination was shown to be better than a single antidepressant considering remission (relative risk [RR], 2.71; 95% confidence interval [CI], 1.69–4.35) and response (RR, 1.55; 95% CI, 1.21–1.97). Mirtazapine plus selective serotonin reuptake inhibitor (SSRI) was superior to an isolated SSRI for remission (RR, 1.88; 95% CI, 1.06–3.33). Tricyclic antidepressant plus SSRI was superior to SSRI for remission and response (RR, 8.58; 95% CI, 1.70–43.32 and RR, 1.78; 95% CI, 1.07–2.93, respectively). There was no difference between combined and monotherapy groups in dropouts owing to adverse effects. The results suggest that antidepressant combination is more efficient than a single antidepressant without a significant decrease in tolerability. However, the small number of clinical trials and methodological problems precludes definitive conclusions.


Radiotherapy and Oncology | 2015

Accelerated partial irradiation for breast cancer: Systematic review and meta-analysis of 8653 women in eight randomized trials

Gustavo Nader Marta; Cristiane R Macedo; Heloisa de Andrade Carvalho; Samir Abdallah Hanna; João Luis Fernandes da Silva; Rachel Riera

BACKGROUND AND PURPOSE Accelerated partial breast irradiation (APBI) is the strategy that allows adjuvant treatment delivery in a shorter period of time in smaller volumes. This study was undertaken to assess the effectiveness and outcomes of APBI in breast cancer compared with whole-breast irradiation (WBI). MATERIAL AND METHODS Systematic review and meta-analysis of randomized controlled trials of WBI versus APBI. Two authors independently selected and assessed the studies regarding eligibility criteria. RESULTS Eight studies were selected. A total of 8653 patients were randomly assigned for WBI versus APBI. Six studies reported local recurrence outcomes. Two studies were matched in 5 years and only one study for different time of follow-up. Meta-analysis of two trials assessing 1407 participants showed significant difference in the WBI versus APBI group regarding the 5-year local recurrence rate (HR=4.54, 95% CI: 1.78-11.61, p=0.002). Significant difference in favor of WBI for different follow-up times was also found. No differences in nodal recurrence, systemic recurrence, overall survival and mortality rates were observed. CONCLUSIONS APBI is associated with higher local recurrence compared to WBI without compromising other clinical outcomes.


Revista Panamericana De Salud Publica-pan American Journal of Public Health | 2010

Estimated annual cost of arterial hypertension treatment in Brazil

Murilo W. Dib; Rachel Riera; Marcos Bosi Ferraz

OBJECTIVES To estimate the direct annual cost of systemic arterial hypertension (SAH) treatment in Brazils public and private health care systems, assess its economic impact on the total health care budget, and determine its proportion of the 2005 gross domestic product (GDP). METHODS A decision tree model was used to determine direct costs based on estimated use of various resources in SAH diagnosis and care, including treatment (medication and non-medication), complementary exams, doctor visits, nutritional assessments, and emergency room visits. RESULTS Estimated direct annual cost of SAH treatment was approximately US


Journal of Affective Disorders | 2013

Antidepressant combination for major depression in incomplete responders—a systematic review

Fábio Lopes Rocha; Cíntia Fuzikawa; Rachel Riera; Melissa Guarieiro Ramos; Cláudia Hara

398.9 million for the public health care system and US


Sao Paulo Medical Journal | 2009

Oral drugs for hypertensive urgencies: systematic review and meta-analysis

Luciana Mendes de Souza; Rachel Riera; Humberto Saconato; Adriana Demathé; Álvaro Nagib Atallah

272.7 million for the private system, representing 0.08% of the 2005 GDP (ranging from 0.05% to 0.16%). With total health care expenses comprising about 7.6% of Brazils GDP, this cost represented 1.11% of overall health care costs (0.62% to 2.06%)-1.43% of total expenses for the Unified Healthcare System (Sistema Unico de Saúde, SUS) (0.79% to 2.75%) and 0.83% of expenses for the private health care system (0.47% to 1.48%). Conclusion. To guarantee public or private health care based on the principles of universality and equality, with limited available resources, efforts must be focused on educating the population on prevention and treatment compliance in diseases such as SAH that require significant health resources.


Revista Brasileira De Reumatologia | 2003

Osteoporose - a importância da prevenção de quedas

Rachel Riera; Virginia Fernandes Moça Trevisani; João Paulo Nogueira Ribeiro

BACKGROUND Antidepressant combination has been suggested as a strategy to increase treatment efficacy. The objective of this study was to perform a systematic review and meta-analysis of studies that assessed the effect of antidepressant combination for major depression in patients with incomplete response to an initial antidepressant. METHODS Studies were retrieved from PubMed (1966-February, 2012), Cochrane Library (-February, 2012), Embase (1980-February, 2012), PsycINFO (1980-February, 2012), Lilacs (1982-February, 2012), clinical trials registry, thesis database (www.capes.gov.br), and secondary references. Included studies had an open label phase in which an initial antidepressant was used for the treatment of major depression and a double blind phase for the incomplete responders that compared monotherapy with the first antidepressant versus the association of a second antidepressant to the first one. RESULTS Out of the 4,884 studies retrieved, only five satisfied the inclusion criteria. The total number of patients included was 483. Only two small trials reported benefits of adding a second antidepressant to the initial antidepressant. Dropouts due to side effects were not reported in three studies. Meta-analysis was not performed due to the small number of studies, the inconsistency in the direction of effect and the possible instability of effect size. Only limited kinds of combination, involving mianserin, mirtazapine and desipramine were studied. Some properties of the first two drugs such as the anxiolytic, sedative, and orexigenic effects, can mimic depression improvement. LIMITATIONS Publication bias cannot be ruled out. Only one study included a monotherapy arm with the antidepressant used for augmentation of the first antidepressant. CONCLUSIONS The practice of using a combination of antidepressants for major depression in incomplete responders is not warranted by the literature.


Sao Paulo Medical Journal | 2008

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review

Virginia Fernandes Moça Trevisani; Rachel Riera; Aline Mizusaki Imoto; Humberto Saconato; Álvaro Nagib Atallah

CONTEXT AND OBJECTIVE Hypertensive urgencies are defined as severe elevations in blood pressure without evidence of acute or progressive target-organ damage. The need for treatment is considered urgent but allows for slow control using oral or sublingual drugs. If the increase in blood pressure is not associated with risk to life or acute target-organ damage, blood pressure control must be implemented slowly over 24 hours. For hypertensive urgencies, it is not known which class of antihypertensive drug provides the best results and there is controversy regarding when to use antihypertensive drugs and which ones to use in these situations. The aim of this review was to assess the effectiveness and safety of oral drugs for hypertensive urgencies. METHODS This systematic review of the literature was developed at the Brazilian Cochrane Center, and in the Discipline of Emergency Medicine and Evidence-Based Medicine at the Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp-EPM), in accordance with the methodology of the Cochrane Collaboration. RESULTS Sixteen randomized clinical trials including 769 participants were selected. They showed that angiotensin-converting enzyme inhibitors had a superior effect in treating hypertensive urgencies, evaluated among 223 participants. The commonest adverse event for calcium channel blockers were headache (35/206), flushing (17/172) and palpitations (14/189). For angiotensin-converting enzyme inhibitors, the principal side effect was bad taste (25/38). CONCLUSIONS There is important evidence in favor of the use of angiotensin-converting enzyme inhibitors for treating hypertensive urgencies, compared with calcium channel blockers, considering the better effectiveness and the lower frequency of adverse effects (like headache and flushing).


Revista Brasileira De Reumatologia | 2006

Revisões sistemáticas e metanálises na reumatologia

Rachel Riera; Mirhelen Mendes de Abreu; Rozana Mesquita Ciconelli

The population growth for individuals over 60 years old has been intensified in the past thirty years in our country. This demographic change leads to epidemiological transition, characterized by the decrease of childhood death rate, reduction of infectious diseases and increase of chronic degenerate disease, such as osteoporosis. The mortality and morbidity increase due to osteoporosis has been associated with substantial economic costs attributed to hospitalization, admission to an institution, disabilities and premature deaths. Fracture is the clinical consequence of osteoporosis. Then, the evaluation of the environment at home in order to identify and remove hazards is very important as prevention strategy for falls, since they are the leading cause of more than 85% of fractures. So, it is important to remember that falls are common and considered as high morbidity events in the elderly living in communities. The challenge to the rheumatology clinician and other health professionals is the early recognition of risk factors for osteoporosis and falling; the education of patients and the intervention during the whole life, for both, men and women, is still a conduct not much developed in our community.


BJUI | 2012

Satisfaction with the treatment, confidence and 'naturalness' in engaging in sexual activity in men with psychogenic erectile dysfunction: preliminary results of a randomized controlled trial of three therapeutic approaches.

Tamara Melnik; Carmita Helena Najjar Abdo; Jose F. de Moraes; Rachel Riera

CONTEXT AND OBJECTIVE Osteoporosis is defined as a disease characterized by low bone mass and deterioration of the bone tissue microarchitecture. Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation, thus promoting bone tissue increase. The aim was to assess the effectiveness and safety of teriparatide for treating postmenopausal osteoporosis. METHODS A systematic review was conducted using the Cochrane Collaboration methodology. RESULTS 1) Teriparatide 20 microg or 40 microg versus placebo: there was a benefit from teriparatide, considering the following outcomes: reduction in the number of new vertebral and non-vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density. 2) Teriparatide 40 microg versus alendronate 10 mg/day for 14 months: there was no statistical difference regarding the incidence of new vertebral or non-vertebral fractures, although in the group that received teriparatide there was greater bone mineral density increase in the whole body, lumbar column and femur. 3) Estrogen plus teriparatide 25 microg versus estrogen: there was a benefit, considering the following outcomes: reduction in the number of new vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density after three years. CONCLUSIONS When teriparatide is intermittently administered in low doses, it reduces the incidence of vertebral fractures (67%) and non-vertebral fractures (38%) and increases bone mineral density in the lumbar column and femur. There is a need for studies with longer observation in order to allow conclusions regarding the safety and duration of the therapeutic effects.

Collaboration


Dive into the Rachel Riera's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maria Regina Torloni

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Rafael Leite Pacheco

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Álvaro Nagib Atallah

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antonio Jose Grande

Universidade do Extremo Sul Catarinense

View shared research outputs
Top Co-Authors

Avatar

Tiago B de Castria

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Valter Silva

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Carolina de Oliveira Cruz

Federal University of São Paulo

View shared research outputs
Researchain Logo
Decentralizing Knowledge